Hepion Pharmaceuticals CFO John Brancaccio resigns; interim CFO named

Hepion Pharmaceuticals, Inc.

John Brancaccio resigned as CFO and director effective June 30, 2025, for personal reasons.
Kaouthar Lbiati assumes role of Interim Chief Financial Officer as of the filing date.
No permanent successor has been announced; company is a clinical-stage biotech (HEPA).

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.